Literature DB >> 6123719

Single-dose penicillin prophylaxis of neonatal group-B-streptococcal disease.

J D Siegel, G H McCracken, N Threlkeld, B M DePasse, C R Rosenfeld.   

Abstract

The efficacy of a single dose of aqueous penicillin G in preventing neonatal group-B streptococcal infections was demonstrated in a randomised study conducted over 41 months. 16 082 infant received a single dose of penicillin within one hour of delivery, and 15 976 infants who received tetracycline ophthalmic ointment served as the control group. Group-B streptococcal systemic infections were significantly less common in the penicillin-treated infants (0.6 vs 1.7 cases per 100 live birth, p = 0.004). The incidence of infection caused by penicillin-resistant pathogen was insignificantly increased in the penicillin group (2.2 vs 1.6 cases per thousand live birth, p = 0.32). this difference was accounted for almost completely by the events of the first 12 months of the study period when, for unexplained reasons, there was a considerable increase in the number of penicillin-resistant infections in the penicillin group (3.6 vs 1.4 cases per 1000 live births, p = 0.09). The mortality associated with penicillin-susceptible pathogens was higher in the control group (0.1 vs 0.4 per 1000 live births, p = 0.18). However, the mortality associated with penicillin-resistant pathogens was increased in the penicillin (0.4 vs 1.0 per 1000 live births, p = 0.06). The combined mortality rates for all pathogens were not significantly different (1.1 vs 0.7 per 1000 liver births, p = 0.27, for the penicillin and control groups, respectively) and were nearly equivalent when the excess number of deaths associated with penicillin-resistant infections in the penicillin group during the first study year was excluded from analysis. The incidence of gonococcal ophthalmia and conjunctivitis was unaffected by the use of intramuscular penicillin at birth.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6123719     DOI: 10.1016/s0140-6736(82)92449-7

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  13 in total

1.  The prevention of early-onset group B streptococcal infections in the newborn.

Authors: 
Journal:  Can J Infect Dis       Date:  1994-11

Review 2.  Chemoprophylaxis of group B streptococcal infections.

Authors:  S P Gotoff
Journal:  Infection       Date:  1997 Jul-Aug       Impact factor: 3.553

3.  Immunoprophylaxis and immunotherapy of neonatal group B streptococcal infections.

Authors:  S P Gotoff
Journal:  Infection       Date:  1985       Impact factor: 3.553

4.  Immunoprophylaxis and immunotherapy of neonatal group B streptococcal infections.

Authors:  S P Gotoff
Journal:  Infection       Date:  1984 Mar-Apr       Impact factor: 3.553

Review 5.  Neonatal infections: group B streptococcus.

Authors:  Paul Trafford Heath; Luke Anthony Jardine
Journal:  BMJ Clin Evid       Date:  2010-09-27

Review 6.  Neonatal infections: group B streptococcus.

Authors:  Paul T Heath; Luke Anthony Jardine
Journal:  BMJ Clin Evid       Date:  2014-02-28

Review 7.  Penicillins. A current review of their clinical pharmacology and therapeutic use.

Authors:  Dilip Nathwani; Martin J Wood
Journal:  Drugs       Date:  1993-06       Impact factor: 9.546

Review 8.  Neonatal infections: group B streptococcus.

Authors:  James Hanley
Journal:  BMJ Clin Evid       Date:  2008-01-16

9.  Effectiveness of intrapartum penicillin prophylaxis in preventing early-onset group B streptococcal infection: results of a meta-analysis.

Authors:  U D Allen; L Navas; S M King
Journal:  CMAJ       Date:  1993-12-01       Impact factor: 8.262

Review 10.  Epidemiology of group B streptococcal disease in the United States: shifting paradigms.

Authors:  A Schuchat
Journal:  Clin Microbiol Rev       Date:  1998-07       Impact factor: 26.132

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.